These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24124139)

  • 1. Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients.
    Winkler AM; Tormey CA;
    Am J Clin Pathol; 2013 Nov; 140(5):610-22. PubMed ID: 24124139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.
    Liew A; Eikelboom JW; O'Donnell M; Hart RG
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S34-44. PubMed ID: 23790596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Anticoagulation Reversal Focus on Direct Thrombin Inhibitors and Factor Xa Inhibitors.
    Mancl EE; Crawford AN; Voils SA
    J Pharm Pract; 2013 Feb; 26(1):43-51. PubMed ID: 23160865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology consultation on anticoagulation monitoring: factor X-related assays.
    Wool GD; Lu CM;
    Am J Clin Pathol; 2013 Nov; 140(5):623-34. PubMed ID: 24124140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
    Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
    Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
    van Ryn J; Grottke O; Spronk H
    Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory monitoring of new anticoagulants.
    Castellone DD; Van Cott EM
    Am J Hematol; 2010 Mar; 85(3):185-7. PubMed ID: 20131309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal)].
    Vicente V; Martín A; Lecumberri R; Coll-Vinent B; Suero C; González-Porras JR; Marco P; Mateo J; Roldán V; Soulard S; Crespo C; Camats M;
    Emergencias; 2017 Feb; 29(1):18-26. PubMed ID: 28825264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monitoring of Oral Thrombin Inhibitor].
    Matsuno K; Usami T; Hatuse M; Shimizu C
    Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
    Dickneite G; Hoffman M
    Thromb Haemost; 2014 Feb; 111(2):189-98. PubMed ID: 24136202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.
    Miyares MA; Davis K
    Am J Health Syst Pharm; 2012 Sep; 69(17):1473-84. PubMed ID: 22899742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G; Roser M; Nauck M
    Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.
    Salmela B; Joutsi-Korhonen L; Armstrong E; Lassila R
    Semin Thromb Hemost; 2012 Feb; 38(1):23-30. PubMed ID: 22314600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors.
    Alouidor B; Sweeney RE; Tat T; Wong RK; Yoon JY
    J Extra Corpor Technol; 2019 Mar; 51(1):29-37. PubMed ID: 30936586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
    Kaatz S; Kouides PA; Garcia DA; Spyropolous AC; Crowther M; Douketis JD; Chan AK; James A; Moll S; Ortel TL; Van Cott EM; Ansell J
    Am J Hematol; 2012 May; 87 Suppl 1():S141-5. PubMed ID: 22473649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.